Funding

Stellular Bio

United States · Biotech

Develops platelet-derived regenerative biologic therapeutics for ocular surface diseases

Visit stellularbio.comFunding history

Funding history

1 round · 0 with disclosed amounts
AnnouncedRoundAmountInvestors
Series AUndisclosedCockrell Interests — Role not disclosedZiff Capital Partners — Role not disclosed

Investors

Cockrell InterestsSeries AZiff Capital PartnersSeries A

Coverage

Jan 28, 2026Stellular Bio · Series A

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcesstellularbio.com ↗